Presentations will include an update on Amryt’s long-term strategy, the global market opportunity for Amryt’s three commercial products and Amryt’s growth plans for Mycapssa® post its recent acquisition of Chiasma, Inc. Mycapssa® is the first and only FDA-approved oral somatostatin analog (SSA) for acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. Mycapssa® also has the potential to expand into the neuroendocrine tumor (NET) market and has a confirmed modified 505(b)(2) regulatory pathway.

Leading KOL, Dr. Maria Fleseriu, FACE (Oregon Health & Science University) will join the webinar to discuss the current treatment landscape in acromegaly.

Amryt management will also provide an update on their lead development candidate, Oleogel-S10 including a discussion on the regulatory pathway for Oleogel-S10 and their global commercialization and launch readiness plans for Oleogel-S10, if approved. Oleogel-S10 is a potential treatment for Epidermolysis Bullosa (EB), for which there is currently no approved treatment.

A question and answer session will follow the presentations.